Key facts
- Axol Bioscience’s last known valuation is $128.1M (Aug 2017).
- It has raised $19.9M; the latest was Later Stage VC ($2.8M) in Jan 2026.
- Notable investors include Scottish Enterprise, SyndicateRoom, Cambridge Angels, Amadeus Capital Partners, Meltwind Advisory — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Axol Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Axol Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Axol Bioscience
Operator of a biotechnology company intended for medical research, disease modeling, and drug development. The company generates stem cells from blood and tissue cells, extracted from healthy and diseased patients, to develop the best human cell biology research tools, which can advance medical research and drug discovery for many of the world's biggest and best-known pharma companies and research institutions, enabling researchers to develop treatments based on stem cell research.
- Sector
- Healthcare
- HQ
- Roslin, United Kingdom
- Founded
- 2013
- Employees
- 46
- Website
- axolbio.com/
- Ownership
- Privately Held (backing)
Axol Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Axol Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Axol Bioscience in its N-PORT filings yet. We sweep new filings monthly.